The Technical Analyst
Caribou Biosciences, Inc. [CRBU]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Caribou Biosciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-3.10% $4.07
America/New_York / 15 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 367.58 mill |
| EPS: | -1.380 |
| P/E: | -2.95 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 90.31 mill |
| Avg Daily Volume: | 1.590 mill |
| RATING 2024-04-15 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -2.95 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.50x |
| Company: PE -2.95 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 3.60 - 4.54 ( +/- 11.62%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-20 | O'byrne Jason | Buy | 153 000 | Option to purchase Common Stock |
| 2024-02-20 | O'byrne Jason | Buy | 33 000 | Common Stock |
| 2024-02-20 | Mcclung Barbara G | Buy | 33 000 | Common Stock |
| 2024-02-20 | Mcclung Barbara G | Buy | 153 000 | Option to purchase Common Stock |
| 2024-02-20 | Khan Ruhi Ahmad | Buy | 153 000 | Option to purchase Common Stock |
| INSIDER POWER |
|---|
| 93.01 |
| Last 96 transactions |
| Buy: 4 096 718 | Sell: 409 985 |
Forecast:
16:00 - $4.07
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.07
Forecast 2: 16:00 - $4.07
Forecast 3: 16:00 - $4.07
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.07 (-3.10% ) |
| Volume | 1.583 mill |
| Avg. Vol. | 1.590 mill |
| % of Avg. Vol | 99.56 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CRBU
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $6.82 | N/A | Active |
|---|
CRBU
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Latest Press Releases
2024-04-15 09:00:00 - Press Release
Caribou Biosciences Announces Oral Presentation On In Vivo Cas12a Chrdna Genome Editing At The 27th Annual Meeting Of The American Society Of Gene And Cell Therapy (asgct)
Berkeley, calif., april 15, 2024 (globe newswire) -- caribou biosciences, inc. (nasdaq: crbu), a leading clinical-stage crispr genome-editing biopharmaceutical company, today announced an abstract on the efficient use of cas12a chrdna genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27th annual meeting of the american society of gene and cell therapy (asgct), which is being held may 7-11, 2024, in baltimore, maryland.
2024-04-04 16:00:00 - Press Release
Caribou Biosciences Expands Clinical Development Of Cb-010 With Fda Clearance Of Ind In Lupus
-- fda has cleared caribou's ind application for cb-010 in lupus nephritis and extrarenal lupus; gallop phase 1 clinical trial expected to initiate by ye 2024 -- -- driven by encouraging initial safety and efficacy in the ongoing antler trial for r/r b-nhl, cb-010 clinical development has expanded to include autoimmune diseases --
2024-03-20 10:00:00 - Press Release
Hireright Holdings Corp. (hrt) Investigation: Bronstein, Gewirtz & Grossman, Llc Encourages Investors To Seek Compensation For Alleged Wrongdoings
New york--(business wire)---- $crbu #classaction--attorney advertising--bronstein, gewirtz & grossman, llc is investigating potential claims on behalf of purchasers of hireright holdings corp. (“hireright holdings” or “the company”) (nyse: hrt). investors who purchased hireright holdings securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/hrt. investigation details: the investigation into hireright holdings focuses on its proposed sale to.
2024-03-11 16:05:00 - Press Release
Caribou Biosciences Reports Fourth Quarter And Full Year 2023 Financial Results And provides Business Update
-- 30 th patient dosed in cb-010 antler phase 1 trial dose expansion; initial dose expansion data and rp2d to be disclosed in q2 2024 -- -- 1 st patient dosed in cb-012 amplify phase 1 trial for patients with r/r aml --
2024-02-15 16:05:00 - Press Release
Caribou Biosciences To Participate In Upcoming Investor Conferences
Berkeley, calif., feb. 15, 2024 (globe newswire) -- caribou biosciences, inc. (nasdaq: crbu), a leading clinical-stage crispr genome-editing biopharmaceutical company, today announced the company's participation in the following investor conferences:
Latest News
2024-03-14 13:01:10 - Zacks Investment Research
All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy
Caribou Biosciences, Inc. (CRBU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2024-03-12 12:37:04 - The Motley Fool
Why Caribou Biosciences Stock Is Crashing Today
Caribou Biosciences announced that it has paused the development of experimental cell therapy CB-020. The company still has three programs in clinical testing.
2024-02-15 16:05:00 - GlobeNewsWire
Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's participation in the following investor conferences:
2024-01-15 08:45:00 - The Motley Fool
3 Biotech Stocks You Can Buy and Hold for the Next Decade
Catalyst buys appealing medicines or pharmaceutical assets and gets them out the door. Recursion uses AI and vast biomedical data to discover and exploit leads for new drugs.
2023-12-13 05:20:00 - InvestorPlace
3 Gene-Editing Stocks With the Potential to Mint Millionaires
Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Drug Administration (FDA) just approved the world's first medicine employing CRISPR technology.
2023-12-08 13:32:25 - Zacks Investment Research
Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?
Caribou Biosciences, Inc. (CRBU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-12-07 05:15:00 - InvestorPlace
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Using gene therapy, companies can change patients' DNA. One type of gene therapy, called CRISPR, largely mimics a method used by bacteria to fend off viruses.
2023-11-26 23:42:58 - Seeking Alpha
Caribou Biosciences: Upcoming CB-010 Data Could Send The Bears Packing
In July, Caribou Biosciences reported positive data from the Antler study of its CAR-T therapy, CB-010, and a $25M investment from PFE. Data from the dose expansion portion of the Antler study are expected in H1'24, but given previous conservative guidance for timelines from CRBU, might come in Q1'24. The Company has $396.7M in cash, which it expects to fund operations into Q4'25.
2023-10-10 05:40:00 - The Motley Fool
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip
Caribou Biosciences stock could rocket up more than 400%, according to the consensus price target from Wall Street analysts. Caribou's lead candidate is an off-the-shelf cellular cancer therapy for lymphoma patients.
2023-09-23 08:45:00 - The Motley Fool
1 Gene Editing Stock to Buy Now, and 1 to Sell
Caribou Biosciences has plenty of money for the next year or so, and great data. Editas Medicine is far behind the competition with its lead programs.